TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of VASER for axillary hyperhidrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of VASER for axillary bromidrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of dysphagia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain on the Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability measured by migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoglobulin Anti-SARS CoV-2 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone densitometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Words Correct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximum Detrusor Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall Safety Profile - Number of Participants Experiencing an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in retinal/choroidal anatomy and/or blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination and Stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of Clostridium difficile anti-toxin Abs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of asymptomatic carrier of Clostridium difficile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrence of thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Berg balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Reach Test (FRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Timed Up and Go (TUG) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Wettability Grade after 12 Hours of Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of suicidality as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline of Simpson-Angus Scale (SAS) Results
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma ABC AUC(0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma 3TC AUC(0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of SCAD and coronary FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in average pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Success Rate at 15 Minutes Post-epidural Bolus Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe Firearm Storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental pain (pulp) threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deviation from the norm of inflammatory and immune mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Renal biopsy gene signature patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in child utterances
Endpoint domain: Life impact
Endpoint subdomain: Communication functioning
Primary endpoint: Safety as Measured by Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of times modifications are needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Four Square Step Test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mini Balance Evaluation Systems Test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Serum Lipid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recording of respiratory mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Success or failure of mechanical ventilation weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival at Six Months
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Symptomatic or Asymptomatic Intracranial Hemorrhage (ICH)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Non-ICH Major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Vaccine-related Serious Clinical Adverse Experiences (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Moderate or Severe Injection-site Pain/Tenderness/Soreness or Swelling
Endpoint domain: Adverse events/effects
Primary endpoint: Sequential fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: procedural times
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Interstitial Glucose Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of the HeartTrends device for myocardial ischemia detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative dose of morphine required to treat NAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest dose of morphine required to treat NAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma drug concentration-time curve at steady state (AUCss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum drug plasma concentration at steady state (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum drug plasma concentration at steady state (Cmin,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interference With Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Brachial Artery Endothelial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients Experiencing Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Median Radiological Progression-Free Survival (rPFS) Time
Endpoint domain: Mortality/survival
Primary endpoint: hypersensitivity reaction to tuberculin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Major Adverse Cardiac Events
Endpoint domain: Mortality/survival
Primary endpoint: Mean Number of Planned and Unplanned Post-mastectomy Surgical Interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in clinic systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Dual Chamber Devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Days Hospitalized
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Multiple In-clinic Visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fecal calprotectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normal range of tidal breathing flow-volume curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SPF change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent signal change in VTA BOLD activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VTA BOLD signal following RTFF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma aciclovir concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic origin determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Daytime Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Florbetapir PET Scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Florbetapir PET Scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Function Score - Peabody Picture Vocabulary Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Function Score - Test of Preschool Early Literacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal IQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication change/no-change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fitness as assessed by Six Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HBV DNA < 50 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients requiring pars plana vitrectomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with sore throat
Endpoint domain: Adverse events/effects
Primary endpoint: Canine root length changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dentin Hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Change in Montreal Cognitive Assessment Total Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of clinical remission at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of patients
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of POI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Visual analog scale (VAS) of sng in the legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale (VAS) of pain in the legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Experiencing Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of galactomannan Antigen (AGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Patients with Periprocedural Vascular Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients with Cerebrovascular Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of General Practices using the e-learning programme
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Renal graft and recipients survival
Endpoint domain: Mortality/survival
Primary endpoint: Serum and peritoneal beta lactams concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of Patients With Increased Levels of Circulating Endothelial Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR = CR + PR) Classified According to RECIST Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evaluation of patients with suspected infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Seizure Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Seizure Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Primary bleeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-inferiority of maintenance therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Varicella IgG Antibody Titer ≥ 1.1 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measles IgG Antibody Titer ≥ 30AU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mumps IgG Antibody Titer ≥ 11AU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rubella IgG Antibody Titer ≥ 15 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival from insulation related adverse events
Endpoint domain: Mortality/survival
Primary endpoint: Quality of life (utility)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: rate of recurrence of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: length of time to first recurrence of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standard deviation of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of Primary Composite Endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Cardiovascular (CV) Death
Endpoint domain: Mortality/survival
Primary endpoint: Intake of dietary key indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Confidence in Team
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in post-bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to Onset of Symptom Relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parastomal recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Subjects With Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of difficult laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Patients With Less Than 15 Letters of ETDRS Visual Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Average Crying and Fussing Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of HIV viral load tests showing virologic suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone marrow suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biomarkers expression in biopsies and exudates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decision-making behavior (actual decisions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision-related BOLD activation (reward regions-of-interest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision-related BOLD activation (executive function regions-of-interest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance (AUC) for detection of fatty liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highly-effective contraceptive use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for Esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Site Infection (SSI) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: cPFS (centrally reviewed cPFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of post operative inguinal Hernia recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Post-operative patient quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain assessed by NRS (Numerical Rating Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ranson score
Endpoint domain: Mortality/survival
Primary endpoint: Grace-Score
Endpoint domain: Mortality/survival
Primary endpoint: sPESI
Endpoint domain: Mortality/survival
Primary endpoint: crb65
Endpoint domain: Mortality/survival
Primary endpoint: CDD
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic value of long noncoding RNA (CCAT1) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in oxygenation
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in hemodynamics
Endpoint domain: Adverse events/effects
Primary endpoint: Circuit breach
Endpoint domain: Adverse events/effects
Primary endpoint: COVID-19 symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Streptococcus pneumoniae nasopharyngeal carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Streptococcus pneumoniae antibiotic susceptibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Enterobacterial intestinal carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Acute Cellular Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events after Viralym-C infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of Presbyopic refractive correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of Presbyopic refractive correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GIP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative incidence of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: BG1h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in tooth position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with AEs Leading to Treatment Discontinuation or Study Withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Amyloid-related Imaging Abnormality-Edema (ARIA-E)
Endpoint domain: Adverse events/effects
Primary endpoint: Amyloid deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: amplitude of Center of Pressure (CoP) displacements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: velocity of Center of Pressure (CoP) displacements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sway area of Center of Pressure (CoP) displacements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Safety during MRI scan
Endpoint domain: Adverse events/effects
Primary endpoint: MRI Safety following MRI scan
Endpoint domain: Adverse events/effects
Primary endpoint: Composite all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Kinetics and Biodistribution of [18F]F-GLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change in Number of Luteinizing Hormone (LH) Pulses Over 10 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Evidence of Follicle Growth From Subcutaneous Kisspeptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Variability in tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Erectile hardness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes